Improved glycemic control with proximal intestinal bypass and weight loss following gastrectomy in non-obese diabetic gastric cancer patients

Ali Guner1,2, Minah Cho1,3, Taeil Son1,3, Hyoung-Il Kim1,3, Sung Hoon Noh1,3 and Woo Jin Hyung1,3

1Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
2Department of General Surgery, Karadeniz Technical University College of Medicine, Farabi Hospital, Trabzon, Turkey
3Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea

Correspondence to: Woo Jin Hyung, email: wjhyung@yuhs.ac

Keywords: gastric cancer, gastrectomy, diabetes, proximal intestinal bypass, weight loss

Abbreviations: BMI: Body mass index, DM: Diabetes mellitus, HbA1c: Glycosylated hemoglobin

Received: June 24, 2017 Accepted: September 23, 2017 Published: November 01, 2017

ABSTRACT

Purpose: The aim of this study was to assess whether gastrectomy influences glycemic control in non-obese diabetic gastric cancer patients and to identify factors related to glucose metabolism after gastrectomy.

Materials and Methods: We retrospectively analyzed changes in glucose metabolism in 238 non-obese (body mass index < 30 kg/m²) patients with type II diabetes who underwent distal gastrectomy with either gastroduodenostomy (n = 91) or gastrojejunostomy (n = 147) for stage I gastric cancer. We collected demographics, diabetes-related features, surgery-related features, and changes in glucose metabolism during follow-up. The effect of surgery on the course of diabetes was evaluated at different time points according to fasting blood glucose levels and use of diabetes-related medication.

Results: Preoperatively, the mean body mass index was 24.3 ± 2.3. Weight, body mass index and fasting blood glucose of all patients were significantly lower compared to preoperative levels at all time points. Weight loss after 6 months and the percentage of patients whose weight loss ratio was higher than 10% after one year were greater in the gastrojejunostomy group than the gastroduodenostomy group. Overall, 88 (37%) patients showed improvement in their diabetes course at one month after surgery; 152 (64%) showed improvement after 2 years. Duration of diabetes, weight loss, and reconstruction type were associated with improvement in diabetes at different time points. At 6 months and thereafter, the percentage of patients with an improved diabetes course was highest in the gastrojejunostomy plus higher than 10% weight loss group.

Conclusions: Although weight loss may be associated with adverse effects of gastrectomy, postoperative weight loss in an acceptable range is a useful measure of the better glycemic control for the group of diabetic patients. Selecting gastrojejunostomy during gastrectomy and inducing acceptable weight loss after gastrectomy could be beneficial to the non-obese diabetic gastric cancer patients for improved glycemic control.

INTRODUCTION

Development of diagnostic tools and use of mass screening program in East Asia contributed increased early detection and resulted in prolonged survival of gastric cancer patients [1–3]. Comorbid disease has emerged as the leading cause of mortality in gastric cancer patients, rather than cancer itself, especially at earlier stages [4–5].
Impairing physico-emotional health and contributing to lifestyle limitations, type II diabetes mellitus (DM) is the most common comorbidity in gastric cancer patients, with an increasing incidence that has already surpassed 15% [6]. Although diet, exercise, and pharmacotherapy are the primary therapeutic options for treating this progressive disease, surgery has recently been recognized as an effective treatment modality for managing DM [7].

Bariatric surgery was developed as a treatment for helping obese individuals achieve weight loss. Subsequent studies discovered further benefits for bariatric surgery in patients with DM, including improved insulin sensitivity, normalization of plasma glucose levels, and rapid declines in insulin requirements [8–9]. These observations ushered in the use of surgical interventions to manage DM in non-obese individuals, deemed metabolic surgery. Follow-up studies of metabolic surgery in non-obese individuals highlighted improvements in glycemic control similar to those in obese patients after bariatric surgery [10–11].

Metabolic surgery and gastric surgery both result in reduced gastric volume and anatomical reconstruction of the stomach. Additionally, studies suggest that, like metabolic surgery, gastrectomy also elicits favorable changes in glucose metabolism in diabetic gastric cancer patients after surgery [12–14]. However, these studies included patients with advanced stage cancer who received postoperative chemotherapy or chemoradiotherapy or patients who underwent total gastrectomy, which could potentially affect glycemic control. Also, obese patients were included in the studies. Thus, the pure impact of gastrectomy on glucose metabolism in non-obese diabetic gastric cancer patients has not been accurately evaluated.

Herein, we hypothesized that physiological changes in food passage after gastrectomy, together with changes in weight, could influence glucose metabolism in non-obese diabetic gastric cancer patients. Accordingly, we designed this study to assess the effects of changes in food passage and weight on glucose metabolism according to glycemic profiles and to identify an appropriate procedure for surgical reconstruction of the stomach after gastrectomy in gastric cancer patients with type II DM.

RESULTS

Patient characteristics

Of the 238 patients, 179 (75%) were male and 59 (25%) were female. The mean age was 62.9 ± 8 years. The median duration of DM was 8 years (range, 0–36). Only 42 patients (17%) had not used any antidiabetic medication, while the other 196 patients (83%) were prescribed an oral antidiabetic agent, insulin, or both. Preoperatively, the median fasting blood glucose level was 137 mg/dl (range, 61–285 mg/dl) and the median HbA1c was 7.2 (range, 4.5–14.8). Preoperative mean weight and BMI values were 65.9 ± 8 kg and 24.3 ± 2.3, respectively. The median follow-up duration was 58 months (range, 24–97 months).

In total, 147 (62%) patients underwent Billroth-I gastroduodenostomy; 91 (38%) underwent Billroth-II gastrojejunostomy. There were no significant differences between the gastroduodenostomy and groups in terms of age, gender, BMI, BMI class, diabetes-related features, and histopathological features. Mean preoperative weights, however, were significantly different between the reconstruction groups (64.9 ± 8.3 vs 67.5 ± 7.3). The characteristics of all patients and a comparison of the patients grouped according to type of reconstruction are shown in Table 1.

Changes in weight, BMI, fasting blood glucose, and HbA1c

Changes in weight, BMI, fasting blood glucose, and HbA1c were evaluated at 1, 3, 6, 12, and 24 months after surgery. Changes in body weight were shown in Figure 1A. Weight and BMI of all patients were significantly lower compared to preoperative levels at all time points. Compared to the Billroth I gastroduodenostomy group, patients in the Billroth-II gastrojejunostomy group showed greater weight loss after 6 months; moreover, the percentage of patients in the Billroth-II gastrojejunostomy group with a weight loss ratio higher than 10% was significantly greater at 12 and 24 months (Figure 1B–1C).

Fasting blood glucose levels and HbA1c levels of both groups during the follow-up period are shown in Figure 2A–2B. In paired analysis of all patients regardless of the type of reconstruction, fasting blood glucose levels showed statistically significant decrease at all time points, and HbA1c levels at 3 (median 7.2 (4.5–14.8) vs 6.7 (5.5–10.3), p = 0.023) and 12 months (median 7.2 (4.5–14.8) vs 6.8 (6–9), p = 0.033) compared to preoperative levels. Patients in the Billroth-II gastrojejunostomy group had lower levels of fasting blood glucose at 6 and 24 months after surgery than those in the Billroth I gastroduodenostomy group. There were, however, no significant differences in HbA1c levels between the groups throughout the follow-up period.

Factors related to improvement in DM

Improvement in glucose metabolism was evaluated at 1, 3, 6, 12, and 24 months after surgery. A total of 88 patients (37%) showed an improved course of glycemic profile at one month after surgery. The percentages of improved patients were 53% (126 patients), 60% (143 patients), 71% (169 patients), and 64% (152 patients) at 3, 6, 12, and 24 months, respectively.

Univariate analyses were conducted to identify factors contributing to changes in the course of glycemic profile. During the first and third months, no factor was
found to be significantly related with improvement. By the 6th month, preoperative fasting blood glucose level, duration of DM, weight change, and type of reconstruction; by the 12th month, weight change and type of reconstruction.

Table 1: Characteristics of all patients and comparison of groups divided according type of gastric reconstruction

|                        | All patients (n: 238) | Billroth-I gastroduodenostomy (n: 147) | Billroth-II gastrojejunostomy (n: 91) | p value |
|------------------------|-----------------------|----------------------------------------|--------------------------------------|---------|
| Age (year)             | 62.9 ± 8              | 62.9 ± 8.1                             | 63.03 ± 7.9                          | 0.920   |
| Sex                    |                       |                                        |                                      | 0.086   |
| Male                   | 179 (75%)             | 105 (71%)                              | 74 (81%)                             |         |
| Female                 | 59 (25%)              | 42 (29%)                               | 17 (19%)                             |         |
| Duration of diabetes (years) | 8 (0–36)            | 9 (0–36)                               | 7.5 (0–24)                           | 0.075   |
| Weight (kg)            | 65.9 ± 8              | 64.9 ± 8.3                             | 67.5 ± 7.3                           | 0.016   |
| Body mass index (kg/m²) | 24.3 ± 2.3            | 24.1 ± 2.3                             | 24.6 ± 2.2                           | 0.085   |
| Body mass index class<sup>a</sup> |                   |                                        |                                      | 0.210   |
| Normal weight          | 142 (59%)             | 93 (63%)                               | 49 (54%)                             |         |
| Overweight             | 96 (41%)              | 54 (37%)                               | 42 (46%)                             |         |
| Fasting blood glucose (mg/dL) | 137 (61–285)       | 139 (61–261)                           | 131 (67–285)                         | 0.415   |
| HbA1c (%)              | 7.2 (4.5–14.8)        | 7.1 (4.5–14.8)                         | 7.4 (5.7–10.7)                       | 0.607   |
| Antidiabetic treatment |                       |                                        |                                      | 0.805   |
| No treatment           | 42 (17%)              | 27 (18%)                               | 15 (17%)                             |         |
| Oral medication        | 171 (73%)             | 107 (73%)                              | 64 (70%)                             |         |
| Insulin                | 12 (5%)               | 7 (5%)                                 | 5 (5%)                               |         |
| Both                   | 13 (5%)               | 6 (4%)                                 | 7 (8%)                               |         |
| Histology<sup>b</sup>  |                       |                                        |                                      | 0.059   |
| Differentiated         | 159 (67%)             | 105 (71%)                              | 54 (59%)                             |         |
| Undifferentiated       | 79 (33%)              | 42 (29%)                               | 37 (41%)                             |         |
| T classification<sup>c</sup> |                   |                                        |                                      | 0.687   |
| T1                     | 212 (89%)             | 130 (88%)                              | 82 (90%)                             |         |
| T2                     | 26 (11%)              | 17 (12%)                               | 9 (10%)                              |         |
| N classification<sup>c</sup> |                   |                                        |                                      | 0.488   |
| N0                     | 223 (94%)             | 139 (95%)                              | 84 (92%)                             |         |
| N1                     | 15 (6%)               | 8 (5%)                                 | 7 (8%)                               |         |
| Pathological stage<sup>c</sup> |                 |                                        |                                      | 0.928   |
| Stage Ia               | 197 (83%)             | 122 (83%)                              | 75 (82%)                             |         |
| Stage Ib               | 41 (17%)              | 25 (17%)                               | 16 (18%)                             |         |

<sup>a</sup>based on World Health Organization classification
<sup>b</sup>differentiated type includes papillary adenocarcinoma and well or moderately differentiated tubular adenocarcinoma, and undifferentiated type includes poorly differentiated adenocarcinoma, signet-ring cell carcinoma, undifferentiated carcinoma, or mucinous adenocarcinoma.
<sup>c</sup>based on American Joint Committee on Cancer guidelines-7th edition.
of reconstruction; and by the 24th month, duration of DM, weight change, and type of reconstruction were found to be significant factors affecting improvement in glycemic profile (Table 2). In multivariate analysis, duration of DM was shown to be an independent factor for improvement at 24 months; weight change was identified as an independent factor at 6, 12, and 24 months; and type of reconstruction was found to be an independent factor at 6, 12, and 24 months (Table 3).

Effects of weight changes and type of reconstruction on improvement in DM

The Billroth I gastroduodenostomy and Billroth-II gastrojejunostomy groups showed no difference in their percentages of patients with improved glycemic profile for up to 6 months after surgery. Beginning in the 6th month and thereafter, the percentage of patients with improvement in glycemic control was statistically higher for Billroth-II gastrojejunostomy (Figure 3A). Meanwhile, patients experienced a weight loss ratio more than 10% showed significantly higher percentage of improvement in glycemic control at 12 and 24 months than patients experienced a weight loss ratio less than 10% (Figure 3B).

To analyze the combined effect of weight loss and type of reconstruction on glycemic profile, we categorized patients into four groups according to a weight loss ratio of less than or greater than 10%, compared to preoperative weight, and whether they underwent gastroduodenostomy or gastrojejunostomy for gastric reconstruction. The percentages of improved patients in each of the four groups are shown in Figure 3C; statistically significant differences were noted at 6, 12, and 24 months. In logistic regression analysis (reference group is gastroduodenostomy with ≤ 10% weight loss; Table 4), gastrojejunostomy plus ≥ 10% weight loss showed the best improvement (OR: 5.200, 95% CI: 1.424–18.991, p = 0.013 at 6 months; OR: 8.654, 95% CI: 1.928–38.848, p = 0.005 at 12 months, and OR: 5.371, 95% CI: 1.984–14.541, p = 0.001 at 24 months). Gastrojejunostomy plus ≤ 10% weight loss showed the second-best improvement (OR: 2.285, 95% CI: 1.011–5.166, p = 0.047 at 6 months; OR: 2.510, 95% CI: 1.030–6.115, p = 0.043) at 12 months and OR: 4.868, 95% CI: 1.986–11.934, p: 0.001 at 24 months).

DISCUSSION

In this study, we discovered that weight loss and type of reconstruction are associated with improvements in glucose metabolism in non-obese diabetic gastric cancer patients after gastrectomy, together with duration

Figure 1: Changes in body weight (A), weight loss ratio compared to preoperative levels (B) and percentage of patients with a weight loss ratio greater than 10% during the follow-up period (C) according to type of reconstruction. Asterisks indicate statistically significant differences for percentages between groups. BMI: Body mass index.
Table 2: Univariate analysis of variables affecting improvement in glycemic control at different time points after surgery

| Variables                                      | 1st month | 3rd month | 6th month | 12th month | 24th month |
|------------------------------------------------|-----------|-----------|-----------|------------|------------|
| Age                                            | 0.970     | 1.016     | 1.010     | 1.031      | 0.988      |
| Sex (male* vs female)                         | 0.667     | 0.902     | 0.791     | 1.165      | 1.099      |
| Duration of diabetes                          | 0.970     | 0.970     | 0.953     | 0.978      | 0.931      |
| Preoperative weight                           | 0.985     | 0.998     | 1.009     | 1.009      | 1.016      |
| Preoperative BMI                               | 0.871     | 0.984     | 1.106     | 1.087      | 1.032      |
| Preoperative BMI class (normal* vs. overweight)| 0.688     | 0.729     | 1.329     | 1.230      | 1.184      |
| Preoperative fasting blood glucose            | 1.001     | 0.995     | 0.992     | 0.994      | 0.994      |
| Preoperative HbA1c                            | 1.091     | 0.671     | 0.759     | 0.822      | 0.826      |
| Preoperative insulin use (no* vs. yes)        | 0.343     | 0.729     | 1.274     | 1.835      | 0.753      |
| Weight change                                 | 1.164     | 0.939     | 0.909     | 0.920      | 0.907      |
| Method of reconstruction (gastroduodenostomy * vs. gastrojejunostomy) | 0.982 | 1.581 | 2.739 | 4.383 | 5.100 |

OR: Odds ratio, BMI: Body mass index, Asterisk indicates the reference variable.

Figure 2: Fasting blood glucose (A) and HbA1c levels (B). Asterisks indicate statistically significant differences between groups.
of DM. While weight loss resulting from decreased oral intake and reduced absorption after surgery can induce improvements in DM, duodenal bypass has been shown to improve glycemic control in type II DM patients by itself [15–17]. In the present study, nonetheless, we found that weight loss and duodenal bypass act together to improve glucose metabolism after gastrectomy in non-obese patients. Interestingly, gastrojejunostomy elicited better improvement in glycemic profile than gastroduodenostomy by facilitating greater weight loss after surgery in non-obese gastric cancer patients.

Among the non-obese patients included in this study, weight loss after surgery was found to be an independent factor for improvement in DM. For the first 6 months after surgery, weight loss amounts were comparable for gastroduodenostomy and gastrojejunostomy groups; however, in the long term, gastrojejunostomy facilitated greater weight loss, as it, unlike gastroduodenostomy, involved performing proximal intestinal bypass.

Similarly, studies comparing gastric bypass or duodenal-jejunal bypass versus sleeve gastrectomy reported that bariatric procedures that bypassed the proximal intestine achieved greater weight loss than those that did not [18–20]. In accordance with the greater weight loss in the gastrojejunostomy group after 6 months, patients in this group also showed higher rates of improvement in glycemic profile. Meanwhile, however, although improvement in DM after gastric resection may be explained by weight loss, one study has suggested that multiple weight-independent mechanisms affect improvements in DM [21].

Table 3: Multivariate analysis of variables affecting improvement in glycemic control at different time points after surgery

| Variables              | 6th month |          |          | 12th month |          |          | 24th month |          |          |
|------------------------|-----------|----------|----------|------------|----------|----------|------------|----------|----------|
|                        | OR        | 95% CI   | p value  | OR         | 95% CI   | p value  | OR         | 95% CI   | p value  |
| Duration of diabetes   | 0.969     | 0.921–1.019 | 0.197    | —          | —        | —        | 0.944      | 0.897–0.993    | 0.025   |
| Preoperative fasting blood glucose | 0.996 | 0.998–1.003 | 0.226 | — | — | — | 0.028 | 0.929 | 0.877–0.983 | 0.011 |
| Weight change          | 0.922     | 0.860–0.989 | 0.024    | 0.931      | 0.873–0.992 | 0.028    | 0.929      | 0.877–0.983    | 0.011   |
| Method of reconstruction|           |          |          | 0.047      |          | 0.008    |            |          | 0.001    |
| Gastroduodenostomy     | 1 (ref)   |           |          | 1 (ref)    |          | 1 (ref)  |            |          |          |
| Gastrojejunostomy      | 2.128     | 1.010–4.484 | 2.894    | 1.317–6.359 | 3.781    | 1.765–8.098 |            |          |          |

OR: Odds ratio, CI: Confidence interval.

Table 4: Logistic regression analysis of the combined effects of proximal intestinal bypass and weight loss on improved glycemic control

| Group                                      | 6th month |          |          | 12th month |          |          | 24th month |          |          |
|--------------------------------------------|-----------|----------|----------|------------|----------|----------|------------|----------|----------|
|                                           | n         | OR       | 95% CI   | p value    | n         | OR       | 95% CI     | p value  | n         | OR       | 95% CI   | p value  |
| Gastroduodenostomy and ≤ 10% weight loss  | 114       | 1 (ref)  |          |           | 114       | 1 (ref)  |           |          | 110       | 1 (ref)  |          |          |
| Gastroduodenostomy and ≥ 10% weight loss  | 33        | 1.103    | 0.449–2.709 | 0.831    | 33        | 1.879    | 0.716–4.933 | 0.200    | 37        | 2.197    | 0.922–5.237 | 0.076    |
| Gastrojejunostomy and ≤ 10% weight loss  | 60        | 2.285    | 1.011–5.166 | 0.047    | 53        | 2.510    | 1.030–6.115 | 0.043    | 49        | 4.868    | 1.986–11.934 | 0.001    |
| Gastrojejunostomy and ≥ 10% weight loss  | 31        | 5.200    | 1.424–18.991 | 0.013    | 38        | 8.654    | 1.928–38.848 | 0.005    | 42        | 5.371    | 1.984–14.541 | 0.001    |

n: number of patients, OR: Odds ratio, CI: Confidence interval.
facilitates improvement in DM via incretins/anti-incretins, gut hormones or altered bile acid signaling [28–30]. Recently, endoscopically placed medical device which mimics the surgical techniques that provide duodenal bypass, has been shown effective tool for weight loss and metabolic improvement in glucose metabolism [31]. Moreover, because Billroth-II gastrojejunostomy is common in our practice as a reconstruction method after gastrectomy, we evaluated the data of Billroth-II gastrojejunostomy as the group of duodenal bypass, however, we believe Roux-en-Y reconstruction which is another reconstruction technique around the world may achieve similar outcomes.

Beyond the metabolic effects of bypassing duodenum, the length of bypassed segment of proximal intestine is an important point of metabolic surgery and the ideal extent of bypassed segment is still under debate [32]. In this study, remnant stomach was anastomosed to small bowel approximately 20 cm from the ligament of Treitz in gastrojejunostomy group patients. This length is shorter than the length of biliopancreatic limb, which is used in metabolic surgery such as Roux-en-Y gastric bypass or duodenal switch. As was shown in previous studies, we believe that the increasing of the extent of bypassed segment during gastrojejunal anastomosis in gastric cancer surgery may result with better glycemic control [33]. However, this theory should be evaluated in comparative studies.

Another finding of the present study is shorter duration of DM which is typically considered to reflect residual beta cell volume and severity of DM, has positive effect on amelioration of DM [34]. Although DM duration was not associated with improvement in glycemic profile in the early period after surgery, it was by year two. This finding suggests that diabetic patients with a shorter duration of DM and less severe disease might be more likely to experience favorable metabolic outcomes after surgery.

Our retrospective and cross-sectional analysis of the data should be considered as a limitation of this study. As definitions of improvement can vary from study to study, there are limitations to analyzing and comparing data between studies [12, 35–39]. Because we aimed to assess the glucose metabolism according to glycemic profiles in different time points, we used the term “improvement” rather than the term “remission” which requires at least one to five years follow-up period. Nevertheless, since several related conditions may alter diabetes status, we were cautious in selecting patients for inclusion in the study; we exclude individuals who were classified as obese or underweight, who received chemotherapy, who had advanced cancer, or who underwent total gastrectomy. A prospective randomized trial comparing different reconstruction procedures for gastric cancer patients with DM could potentially show which reconstruction type will allow for better improvement and may validate the data of our study. Despite the above limitations, our results provide the rationale for conducting a well-designed prospective study to identify optimal treatment strategies for diabetic patients with gastric cancer. Moreover, our analysis of non-obese patients may provide the necessary evidence with which to expand the application of metabolic surgery to non-obese diabetic patients.

In conclusion, our study showed that reconstruction type and weight loss affect glycemic control in non-obese patients with gastric cancer. The percentage of patients with an improved course of diabetes according to reconstruction type (A), weight loss greater than 10% (B), and both reconstruction type and 10% weight loss (C). No patient in the gastrojejunostomy plus ≥ 10% weight loss group showed improvement during the first month. Asterisks indicate statistically significant differences between groups.
obese diabetic gastric cancer patients. Patients who underwent gastrectomy and were accompanied by more weight loss showed the greatest improvement in glycemic control. Although weight loss may be associated with other adverse effects of gastrectomy, we believe that postoperative weight loss in an acceptable range is a useful measure of the better glycemic control for the group of diabetic patients. Selecting gastrectomy and inducing acceptable weight loss after gastrectomy could be recommendable in non-obese diabetic gastric cancer patients for improved glycemic control.

MATERIALS AND METHODS

Patient selection

We retrospectively reviewed data stored in a prospectively maintained gastric cancer database for patients treated at Severance Hospital of Yonsei University Health System in Seoul, Korea. We selected type II DM patients who underwent distal subtotal gastrectomy for stage I gastric cancer without a history of receiving chemotherapy. There were 252 patients who met the above criteria. Among these, two underweight patients (body mass index [BMI] < 18.5) and 12 obese patients (BMI > 30) were excluded from the analysis. Finally, we analyzed 238 non-obese, type II DM, stage I gastric cancer patients.

Data collection

All data on patient demographics, duration of DM, reconstruction after resection, fasting blood glucose level, glycosylated hemoglobin (HbA1c), body weight, BMI, and types of antidiabetic treatment (oral antidiabetic, insulin, or both) at the time of surgery and periodically during the follow-up period were collected. Patients with fasting blood glucose levels higher than 126 mg/dl or plasma glucose levels at 2 hour after feeding higher than 200 mg/dl were diagnosed as having DM based on criteria set by the World Health Organization [40]. We divided the patients according to the World Health Organization International Classification of BMI: index values between 18.5 and 25 were defined as normal weight, values below 18.5 as underweight, and values between 25 and 30 as overweight. To analyze the effect of surgery on weight changes, we also divided patients into two groups according to weight reductions of less than or greater than 10%.

The effect of surgery on the course of glycemic profile was adapted from the American Society for Metabolic and Bariatric Surgery recommendations and was classified in one of two categories according to fasting blood glucose levels and use of diabetes-related medication [35–36]. The course of diabetes was deemed to have “improved” when patients showed a fasting blood glucose level below 126 mg/dL and either used a lower dose of antidiabetic medication or converted from insulin to oral medication. Patients who experienced no change or an aggravation in medication or fasting blood glucose levels after surgery were defined as having “not-improved”.

Gastric reconstruction

Reconstruction after distal gastrectomy was performed with either Billroth I gastroduodenostomy or Billroth II gastrojejunostomy. While Billroth I gastroduodenostomy is relatively simple to perform, requiring only one anastomosis and allowing for maintenance of physiological intestinal continuity, it can only be performed when relatively a small part of the distal stomach is removed [41]. If achieving a safe tumor margin or acceptable anastomotic tension with gastroduodenostomy is not feasible, surgeons perform a gastrojejunostomy for reconstruction of the stomach. Billroth-II gastrojejunostomy is a gastroenterostomy technique that links the gastric pouch to the jejunum at location 15–20 cm distal to the ligament of Treitz, bypassing the proximal intestine.

Statistical analysis

Continuous variables are presented as means ± standard deviations for a parametric distribution and medians (range) for a nonparametric distribution. The chi-square test, Mann-Whitney U test, and Student’s t test were used to compare categorical and continuous variables as appropriate. The paired analysis was fulfilled by paired t test or Wilcoxon signed-rank test. Univariate and multivariate analyses of variables were performed with logistic regression to identify factors associated with improvement in DM. Statistical analysis software (SPSS 20.0, IBM Corp, Armonk, NY, USA) was used to conduct all statistical analyses. All p-values < 0.05 were considered statistically significant.

Author contributions

Study conception and design: Guner, Hyung, Acquisition of data: Guner, Cho, Son, Hyung, Analysis and interpretation of data: Guner, Cho, Kim, Hyung, Drafting of manuscript: Guner, Son, Hyung, Critical revision: Guner, Cho, Son, Kim, Noh, Hyung.

ACKNOWLEDGMENTS

We would like to thank Anthony Thomas Milliken, ELS (Editing Synthase, Seoul, Korea) for his assistance with editing the manuscript. We also acknowledge the assistance of BioScience Writers, LLC (Houston, TX, USA) with copyediting and correction of English language usage.

CONFLICTS OF INTEREST

The authors have declared no conflicts of interest.
FUNDING

This work was supported by Public-Private Investment Technology Development Program (S2356984).

REFERENCES

1. Kim YG, Kong SH, Oh SY, Lee KG, Suh YS, Yang JY, Choi J, Kim SG, Kim JS, Kim WH, Lee HJ, Yang HK. Effects of screening on gastric cancer management: comparative analysis of the results in 2006 and in 2011. J Gastric Cancer. 2014; 14:129–134.

2. Nishida T, Tsujii M, Kato M, Hayashi Y, Akasaka T, Iijima H, Takehara T. Endoscopic surveillance strategy after endoscopic resection for early gastric cancer. World J Gastrointest Pathophysiol. 2014; 5:100–106.

3. Choi KS, Jun JK, Suh M, Park B, Noh DK, Song SH, Jung KW, Lee HY, Choi JJ, Park EC. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015; 112:608–612.

4. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, Shimada H. Significance of long-term follow-up of early gastric cancer. Ann Surg Oncol. 2006; 13:363–369.

5. Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. Surg Endosc. 2015; 29:2321–2330.

6. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011; 23:1127–1135.

7. Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, Khashyap SR, Kirwan JP, Rogula T, Kroh M, Chang B, Schauer PR. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013; 258:628–636.

8. Johnson RJ, Johnson BL, Blackhurst DW, Bour ES, Cobb WS 4th, Carbonell AM 2nd, Lokey JS, Scott JD. Bariatric surgery is associated with a reduced risk of mortality in morbidly obese patients with a history of major cardiovascular events. Am Surg. 2012; 78:685–692.

9. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Briatore L, Andraghetti G, Catalano M, Cordera R. Effects of gastric bypass on type 2 diabetes in patients with BMI 30 to 35. Obes Surg. 2014; 24:1036–1043.

10. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011; 7:683–690.

11. Reis CE, Alvarez-Leite JI, Bressan J, Alfenas RC. Role of bariatric-metabolic surgery in the treatment of obese type 2 diabetes with body mass index < 35 kg/m²: a literature review. Diabetes Technol Ther. 2012; 14:365–372.

12. Lee W, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH, Yang HK. Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. Obes Surg. 2012; 22:1238–1243.

13. Kang KC, Shin SH, Lee YJ, Heo YS. Influence of gastrectomy for stomach cancer on type 2 diabetes mellitus for patients with a body mass index less than 30 kg/m(2). J Korean Surg Soc. 2012; 82:347–355.

14. Lanzarini E, Csendes A, Lembach H, Molina J, Gutiérrez L, Silva J. Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg. 2010; 34:2098–2102.

15. Zervos EE, Agle SC, Warren AJ, Lang CG, Fitzgerald TL, Dar M, Rotondo MF, Pories WJ. Amelioration of insulin requirement in patients undergoing duodenal bypass for reasons other than obesity implicates foregut factors in the pathophysiology of type II diabetes. J Am Coll Surg. 2010; 210:564–572.

16. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010; 61:393–411.

17. Greenway SE, Greenway FL 3rd, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg. 2002; 137:1109–1117.

18. Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, Tsai MH, Chuang LM. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011; 146:143–148.

19. Garrido-Sanchez L, Murri M, Rivas-Beccera J, Ocaña-Wilhelmi L, Cohen RV, García-Fuentes E, Tinahones FJ. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. Surg Obes Relat Dis. 2012; 8:145–150.

20. Lee WJ, Almulaiif AM, Tsou JJ, Ser KH, Lee YC, Chen SC. Duodenal-jejunal bypass with sleeve gastrectomy versus the sleeve gastrectomy procedure alone: the role of duodenal exclusion. Surg Obes Relat Dis. 2015; 11:765–770.

21. Ting CH, Syu YF, Chen LY, Lee FY, Lee SD, Lee WJ, Chen CY. Perspectives on interventional diabetology: Duodenal exclusion is promising for human type 2 diabetes mellitus remission. Nutrition. 2016; 32:141–145.

22. Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012; 18:49–54.

23. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004; 89:2608–2615.

24. Cohen RV, Rubino F, Schiavon C, Cummings DE. Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis. 2012; 8:e66–e68.
25. Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg. 2004; 14:840–848.

26. Pacheco D, de Luis DA, Romero M, González Sagrado M, Conde R, Izuela O, Aller R, Delgado A. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007; 194:221–224.

27. de Luis D, Domingo M, Romero A, Gonzalez Sagrado M, Pacheco D, Primo D, Conde R. Effects of duodenal-jejunal exclusion on beta cell function and hormonal regulation in Goto-Kakizaki rats. Am J Surg. 2012; 204:242–247.

28. Kwon Y, Abdemur A, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. The foregut theory as a possible mechanism of action for the remission of type 2 diabetes in low body mass index patients undergoing subtotal gastrectomy for gastric cancer. Surg Obes Relat Dis. 2014; 10:235–242.

29. Li JF, Lai DD, Ni B, Sun KX. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013; 56:e158–164.

30. Batterham RL, Cummings DE. Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care. 2016; 39:893–901.

31. Vilarrasa N, de Gordejuela AG, Casajoana A, Duran X, Toro S, Espinet E, Galvao M, Vendrell J, López-Urdiales R, Pérez M, Pujol J. Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism. Obes Surg. 2017; 27:569–577.

32. Kim WS, Kim JW, Ahn CW, Choi SH. Resolution of type 2 diabetes after gastrectomy for gastric cancer with long limb Roux-en-Y reconstruction: a prospective pilot study. J Korean Surg Soc 2013; 84:88–93.

33. Kim JW, Kim KY, Lee SC, Yang DH, Kim BC. The effect of long Roux-en-Y gastrojejunostomy in gastric cancer patients with type 2 diabetes and body mass index < 35 kg/m²: preliminary results. Ann Surg Treat Res. 2015; 88:215–21.

34. Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi A, Natali A, Muscelli E, Mingrone G, Mari A. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004; 53 Suppl 3:S26–33.

35. Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, Ballem N, Kligman M, Kothari S; ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015; 11:489–506.

36. Aminian A, Brethauer SA, Andalib A, Punchai S, Mackey J, Rodriguez J, Rogula T, Kroh M, Schauer PR. Can Sleeve Gastrectomy “Cure” Diabetes? Long-term Metabolic Effects of Sleeve Gastrectomy in Patients With Type 2 Diabetes. Ann Surg. 2016; 264:674–81.

37. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Fried M, Briatore L, D’Alessandro G, Andraghetti G, Cordera R. Effects of biliopancreatic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011; 253:699–703.

38. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Porries WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122:248–250.

39. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How Do We Define Cure of Diabetes? Diabetes Care. 2009; 32:2133–5.

40. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539–553.

41. Xiong JJ, Altaf K, Javed MA, Nunes QM, Huang W, Mai G, Tan CL, Mukherjee R, Sutton R, Hu WM, Liu XB. Roux-en-Y versus Billroth I reconstruction after distal gastrectomy for gastric cancer: a meta-analysis. World J Gastroenterol. 2013; 19:1124–1134.